Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.

Episode 26 December 07, 2022 00:39:02
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.
Few & Far Between: Conversations from the Front Lines of Drug Development
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.

Dec 07 2022 | 00:39:02

/

Show Notes

"Try to find the people who have a really strong background in regulatory science, who really understand the fundamentals, and who you believe can think creatively about the challenges of the cell therapy space." - Chris Min, Longeveron

Biorasi welcomes Chris Min to the Few & Far Between podcast for an inside look at the cell therapy industry and the importance of finding the right team to support your clinical trials. 

Other Episodes

Episode 13

October 27, 2021 00:50:12
Episode Cover

Episode 13: Kelly Franchetti RN, SVP, Global Head Patient Insights and Strategy at YPrime

How has patient advocacy grown to become the driver of rare disease drug development? In today's episode of Biorasi's Few & Far Between podcast,...

Listen

Episode 30

May 03, 2023 00:45:07
Episode Cover

Episode 30, Part One: Dr. Francisco Harrison, CEO and owner, Harrison CST Holding GmbH

"I love clinical research. I will spend my life in clinical research." Dr. Francisco Harrison, CEO and owner, Harrison CST Holding GmbH Biorasi welcomes...

Listen

Episode 49

February 27, 2025 00:35:37
Episode Cover

Episode 49: Eileen Faucher, Principal and Founder, Brass Tacks Health

Today on the Biorasi Few & Far Between podcast: What if you could read a story before its official release? Competitive intelligence gives you...

Listen